Trastuzumab for treatment of refractory/relapsed HER2-positive adult B-ALL: Results of a phase 2 GRAALL study

Blood

Volumn 119, Issue 11, 2012, Pages 2474-2477

  Chevallier, Patrice ^a   Robillard, Nelly ^b   Charbonnier, Aude ^c   Raffoux, Emmanuel ^d   Maury, Sebastien ^e   Carras, Sylvain ^f   Chabrot, Cecile ^g   Fohrer, Cecile ^h   Bernard, Marc ⁱ   Blade, Jean Sebastien ^j   Etienne, Anne ^c   Talmant, Pascaline ^a   Delaunay, Jacques ^a   Guillaume, Thierry ^a   Mohty, Mohamad ^a   Bene, Marie Christine ^k   Ifrah, Norbert ^l   Dombret, Herve ^d  

^a NANTES UNIVERSITY HOSPITAL   (France)

^b HÔTEL DIEU   (France)

^c INSTITUT PAOLI CALMETTES   (France)

^d SAINT LOUIS HOSPITAL   (France)

^e HENRI MONDOR HOSPITAL   (France)

^f HÔPITAL MICHALLON   (France)

^g UNIVERSITY HOSPITAL OF CLERMONT FERRAND   (France)

^h HÔPITAL DE HAUTEPIERRE   (France)

ⁱ RENNES UNIVERSITY HOSPITAL   (France)

^j Military Teaching Hospital Sainte Anne   (France)

^k UNIVERSITY HOSPITAL OF NANCY   (France)

^l ANGERS UNIVERSITY HOSPITAL   (France)

more..

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; TRASTUZUMAB;

ACUTE LYMPHOBLASTIC LEUKEMIA; ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; FEMALE; HIGH RISK POPULATION; HUMAN; HYPERTENSIVE CRISIS; LEUKEMIA RELAPSE; LEUKEMIA REMISSION; LOADING DRUG DOSE; MALE; MONOTHERAPY; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; TREATMENT RESPONSE; TUMOR CELL DESTRUCTION; UNSTABLE ANGINA PECTORIS;

EID: 84858678860     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2011-11-390781     Document Type: Article

References (25)

1. Topp MS, Kufer P, Gökbuget N, et al. Targeted therapy with the T-cell-engaging antibody blinatumomab of chemotherapy-refractory minimal residual disease in B-lineage acute lymphoblastic leukemia patients results in high response rate and prolonged leukemia-free survival. J Clin Oncol. 2011;29(18):2493-2498.
2. Handgretinger R, Zugmaier G, Henze G, et al. Complete remission after blinatumomab-induced donor T-cell activation in three pediatric patients with post-transplant relapsed acute lymphoblastic leukemia. Leukemia. 2011;25(1):181-184.
3. Chevallier P, Robillard N, Houille G, et al. Simultaneous study of five candidate target antigens (CD20, CD22, CD33, CD52, HER2) for antibody-based immunotherapy in B-ALL: a monocentric study of 44 cases. Leukemia. 2009;23(4):806-807.
4. Thomas DA, Faderl S, O'Brien S, et al. Chemoimmunotherapy with Hyper-CVAD plus Rituximab for the treatment of adult Burkitt and Burkitt-type lymphoma or acute lymphoblastic leucemia. Cancer. 2006;106(7):1569-1580.
5. Thomas DA, O'Brien S, Faderl S, et al. Chemoimmunotherapy with a modified hyper-CVAD and rituximab regimen improves outcome in de novo Philadelphia chromosome-negative precursor B-lineage acute lymphoblastic leukemia. J Clin Oncol. 2010;28(24):3880-3889.
6. Raetz EA, Cairo MS, Borowitz MJ, et al. Chemoimmunotherapy reinduction with epratuzumab in children with acute lymphoblastic leukemia in marrow relapse: a Children's Oncology Group Pilot Study. J Clin Oncol. 2008;26(22):3756-3762.
7. Chevallier P, Mahe B, Garand R, et al. Combination of chemotherapy and gemtuzumab ozogamicin in adult Philadelphia positive acute lymphoblastic leukaemia patient harbouring CD33 expression. Int J Hematol. 2008;88(2):209-211.
8. Laporte JP, Isnard F, Garderet L, et al. Remission of adult acute lymphocytic leukaemia with alemtuzumab. Leukemia. 2004;18(9):1557-1558. (Pubitemid 39264085)
9. Tagliabue E, Campiglio M, Pupa SM, et al. Activity and resistance of trastuzumab according to different clinical settings [published online ahead of print, July 2, 2011]. Cancer Treat Rev. doi: 10.1016/j.ctrv.2011.06.002.
10. Cobleigh MA, Vogel CL, Tripathy D, et al. Multinational study of the efficacy and safety of humanized antiHER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. J Clin Oncol. 1999;17(9):2639-2648. (Pubitemid 29415219)
11. Vogel CL, Cobleigh MA, Tripathy D, et al. Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J Clin Oncol. 2002; 20(3):719-726. (Pubitemid 34111379)
12. Marty M, Cognetti F, Maraninchi D, et al. Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study group. J Clin Oncol. 2005;23(19):4265-4274. (Pubitemid 46207001)
13. Piccart-Gebhart MJ, Procter M, Leyland-Jones B, et al. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med. 2005;353(16):1659-1672. (Pubitemid 41464705)
14. Smith I, Procter M, Gelber RD, et al. 2-Year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomized controlled trial. Lancet. 2007;369(9555):29-36. (Pubitemid 46039831)
15. Bang YJ, Van Cutsem E, Feyereislova A, et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastrooesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet. 2010;376(9742):687-697.
16. Chevallier P, Robillard N,Wuilleme-Toumi, et al. Overexpression of Her2/neu is observed in one third of adult acute lymphoblastic leukaemia patients and is associated with chemoresistance in these patients. Haematologica. 2004;89(11):1399-1401. (Pubitemid 39540582)
17. Thomas DA, Kantarjian H, Smith TL, et al. Primary refractory and relapsed adult acute lymphoblastic leukemia: characteristics, treatment results, and prognosis with salvage therapy. Cancer. 1999;86(7):1216-1230. (Pubitemid 29447005)
18. Fielding AK, Richards SM, Chopra R, et al. Outcome of 609 adults after relapse of acute lymphoblastic leukemia (ALL): an MRC UKALL12/ECOG 2993 study. Blood. 2007;109(3):944-950. (Pubitemid 46220637)
19. Tavernier E, Boiron JM, Huguet F, et al. Outcome of treatment after first relapse in adults with acute lymphoblastic leukemia initially treated by the LALA-94 trial. Leukemia. 2007;21(9):1907-1914. (Pubitemid 47299963)
20. Oriol A, Vives S, Hernandez-Rivas JM, et al. Outcome after relapse of acute lymphoblastic leukemia in adult patients included in four consecutive risk-adapted trials by the PETHEMA study Group. Haematologica. 2010;95(4):589-596.
21. Slamon DJ, Leyland-Jones B, Shak S, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that over-expresses HER2. N Engl J Med. 2001;344(11):783-792. (Pubitemid 32222155)
22. Zent CS, Call TG, Shanafelt TD, et al. Early treatment of high-risk chronic lymphoblastic leukaemia with alemtuzumab and rituximab. Cancer. 2008;113(8):2110-2118.
23. Nijmeijer BA, van Schie ML, Halkes CJ, et al. A mechanistic rationale for combining alemtuzumab and rituximab in the treatment of ALL. Blood. 2010;116(26):5930-5940.
24. Baselga J, Cortes J, Kim SB, et al. Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer. N Engl J Med. 2012;366(2):109-119.
25. Albarello L, Pecciarini L, Doglioni C. HER2 testing in gastric cancer. Adv Anat Pathol. 2011;18(1):53-59.